Svenja Petersohn

4PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples and disability
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 26, 2023
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.

Nishit Dhanji, Tassia Cristina Decimoni, Matthew T D Dyer

|Jul 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.

Svenja Petersohn, Bradley McGregor, Sven L Klijn

|May 25, 2022
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.

Svenja Petersohn, Gilles Salles, Michael Wang

|Apr 01, 2019
Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments.

Svenja Petersohn, Bram L T Ramaekers, Renske H Olie

Pageof 1

Frequent Collaborators

1 joint publications

Gilles Salles

1 joint publications

Michael Wang

1 joint publications

Jim Wu

1 joint publications

Sally W Wade